• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan).非小细胞肺癌的预后因素:日本国立癌症中心医院的多元回归分析
J Cancer Res Clin Oncol. 1987;113(6):563-6. doi: 10.1007/BF00390866.
2
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益:系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
6
A systematic overview of chemotherapy effects in non-small cell lung cancer.非小细胞肺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):327-39. doi: 10.1080/02841860151116402.
7
Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.针对非小细胞肺癌引起胸部症状患者的姑息性放疗方案。
Cochrane Database Syst Rev. 2015 Jan 14;1(1):CD002143. doi: 10.1002/14651858.CD002143.pub4.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.
10
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体(EGFR)突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.

引用本文的文献

1
The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC.精准医学中被忽视的基石:非小细胞肺癌的个性化术后监测计划
JTO Clin Res Rep. 2024 Jun 27;5(8):100701. doi: 10.1016/j.jtocrr.2024.100701. eCollection 2024 Aug.
2
Imaging features and prognostic value of F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.肺癌软组织转移 F-FDG PET/CT 检测的影像学特征及其预后价值:一项回顾性研究。
BMC Cancer. 2020 Jun 26;20(1):596. doi: 10.1186/s12885-020-07080-0.
3
Prognostic value of site-specific metastases in lung cancer: A population based study.肺癌特定部位转移的预后价值:一项基于人群的研究。
J Cancer. 2019 Jun 2;10(14):3079-3086. doi: 10.7150/jca.30463. eCollection 2019.
4
Specific organ metastases and survival in metastatic non-small-cell lung cancer.转移性非小细胞肺癌的特定器官转移与生存情况
Mol Clin Oncol. 2015 Jan;3(1):217-221. doi: 10.3892/mco.2014.410. Epub 2014 Sep 4.
5
Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.接受化疗的IV期非小细胞肺癌(NSCLC)患者的预处理临床预后因素。
J Cancer Res Clin Oncol. 2003 Feb;129(2):114-22. doi: 10.1007/s00432-002-0408-4. Epub 2003 Mar 7.
6
Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.顺二氯二氨铂(II)持续5天输注治疗非小细胞肺癌的II期研究。
Cancer Chemother Pharmacol. 1990;26(6):389-92. doi: 10.1007/BF02994086.
7
A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.含顺铂联合化疗治疗晚期非小细胞肺癌的预后因素风险指数
Cancer Chemother Pharmacol. 1992;30(1):1-6. doi: 10.1007/BF00686477.

本文引用的文献

1
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.顺铂与长春地辛联合化疗治疗晚期肺癌:一项比较两种给药方案的随机试验。
Ann Intern Med. 1981 Oct;95(4):414-20. doi: 10.7326/0003-4819-95-4-414.
2
Prognostic factors for survival in patients with inoperable lung cancer.无法手术的肺癌患者生存的预后因素
J Natl Cancer Inst. 1980 Jul;65(1):25-32.
3
Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).
Cancer. 1982 Dec 15;50(12):2751-6. doi: 10.1002/1097-0142(19821215)50:12<2751::aid-cncr2820501210>3.0.co;2-3.
4
Illusion and reality: practical pitfalls in interpreting clinical trials.幻想与现实:解读临床试验中的实际陷阱
J Clin Oncol. 1984 May;2(5):488-97. doi: 10.1200/JCO.1984.2.5.488.
5
Importance of prognostic factors in cancer clinical trials.
Cancer Treat Rep. 1984 Jan;68(1):185-92.
6
Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.
Cancer Treat Rep. 1983 Jul-Aug;67(7-8):727-30.
7
Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.培普利欧霉素联合卡巴醌与丝裂霉素对非小细胞肺癌的作用
Cancer Treat Rep. 1983 Apr;67(4):385-7.
8
Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens.
J Clin Oncol. 1985 Jan;3(1):72-9. doi: 10.1200/JCO.1985.3.1.72.
9
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.转移性非小细胞肺癌的长期生存者:东部肿瘤协作组研究
J Clin Oncol. 1986 May;4(5):702-9. doi: 10.1200/JCO.1986.4.5.702.
10
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.转移性非小细胞肺癌四种最有效治疗方案的随机试验。
J Clin Oncol. 1986 Jan;4(1):14-22. doi: 10.1200/JCO.1986.4.1.14.

非小细胞肺癌的预后因素:日本国立癌症中心医院的多元回归分析

Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan).

作者信息

Sakurai M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Miura K, Fujiwara Y, Otsu A, Horiuchi N, Nakano H

机构信息

Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.

出版信息

J Cancer Res Clin Oncol. 1987;113(6):563-6. doi: 10.1007/BF00390866.

DOI:10.1007/BF00390866
PMID:2824522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12248321/
Abstract

A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical administration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0-1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.

摘要

回顾性分析了190例无法切除的非小细胞肺癌(NSCLC)患者,研究8个治疗前因素和3个与治疗相关的预后因素对生存的影响。根据东京国立癌症中心医院1980年4月至1985年12月进行的II期或III期试验方案,所有患者均接受了化疗,部分患者还接受了胸部放疗。所选的8个治疗前因素为体能状态、性别、分期、年龄、组织学类型以及脑、骨或肝转移情况。3个与治疗相关的因素为原发部位的放射治疗、对化疗的反应以及顺二氯二氨铂(II)(CDDP)临床应用前后的治疗周期。190例患者中,71例(37.4%)存活超过1年,但化疗开始后仅17例(8.9%)存活2年。单因素分析显示,体能状态0 - 1级、女性、无骨或肝转移、对化疗有反应以及CDDP应用后的治疗周期被认为是有利的预后因素。多因素回归分析表明,体能状态、性别以及CDDP应用后的治疗周期是长期生存的重要因素。考虑这些预后因素能够更准确地评估化疗效果,建议在晚期NSCLC患者进入随机对照试验前,根据体能状态和性别进行分层。